Journals / Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi / 2013 / Cilt: 26 - Sayı: 3

Şizofreni hastalarında metabolik sendrom sıklığının sosyodemografik ve klinik özelliklerle ilişkisi

The correlation between incidence of metabolic syndrome and sociodemographic and clinical characteristics in schizophrenia patients

Pages
267–275
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There would seem to be no correlation between MetS and schizophrenia subtypes and symptoms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The purpose of this study was to determine the frequency of metabolic syndrome (MetS) in schizophrenia patients who are receiving treatment with antipsychotic drugs and also the sociodemographic and clinical characteristics of schizophrenia patients with MetS.
📊
Key Findings & Data:Methods: 111 schizophrenia patients diagnosed on the basis of DSM-IV diagnostic criteria and receiving antipsychotic therapy for at least 3 months were included in the study.
💡
Conclusion & Impact:There would seem to be no correlation between MetS and schizophrenia subtypes and symptoms.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The purpose of this study was to determine the frequency of metabolic syndrome (MetS) in schizophrenia patients who are receiving treatment with antipsychotic drugs and also the sociodemographic and clinical characteristics of schizophrenia patients with MetS. Methods: 111 schizophrenia patients diagnosed on the basis of DSM-IV diagnostic criteria and receiving antipsychotic therapy for at least 3 months were included in the study. MetS was diagnosed on the basis of International Diabetes Fedaration (IDF) diagnostic criteria. Schizophrenia patient groups with and without diagnosed MetS were compared in terms of sociodemographic and clinical characteristics. Results: MetS was determined in 27% of the patients. The most commonly determined parameter was elevated waist circumference (65.8%). The least common parameter was elevated blood pressure (10.8%). The waist circumference parameter in women and the blood pressure parameter in men were more frequently determined. No difference was determined between schizophrenia patients with or without MetS in terms of sociodemographic characteristics, schizophrenia subtypes and symptoms or other clinical characteristics. Conclusion: MetS is a significant problem in schizophrenia patients receiving antipsychotic therapy. Elevated waist circumference is an important parameter in monitoring. The findings in the literature regarding the relationship between MetS and sociodemographic and clinical characteristics are contradictory. No correlation was determined in our study. Further studies are now needed to shed light on this subject. There would seem to be no correlation between MetS and schizophrenia subtypes and symptoms.

Özet

Amaç: Bu çalışmada, antipsikotik ilaçlarla tedavi altında olan şizofreni hastalarında metabolik sendrom (MetS) sıklığı ve metabolik sendromlu hastaların sosyodemografik ve klinik özelliklerinin saptanması amaçlanmıştır. Yöntem: DSM-IV tanı kriterlerine göre tanısı konan ve en az 3 aydır antipsikotik tedavi almakta olan 111 şizofreni hastası çalışmaya alındı. MetS tanısı Uluslararası Diyabet Fedarasyonu (IDF) tanı kriterlerine göre kondu. MetS tanısı konan ve konmayan hasta grupları arasında sosyodemografik ve klinik özellikler açısından karşılaştırma yapıldı. Bulgular: Hastaların %27’sinde MetS saptandı. En sık saptanan kriter, bel çevresi genişliğiydi (%65.8). Sıklığı en az olan kriter ise kan basıncı yüksekliğiydi (%10.8). Bel çevresi genişliği kriteri kadınlarda, kan basıncı yüksekliği kriteri ise erkeklerde daha sık karşılandı. MetS’i olan ve olmayan şizofreni hastaları arasında sosyodemografik özellikler, şizofreni tipi, semptomları ve diğer klinik özellikler açısından fark saptanmadı. Sonuç: Antipsikotik tedavi altında olan şizofreni hastalarında MetS önemli bir sorundur. Bel çevresi genişliği takipte önemli bir kriterdir. Literatürde MetS ile sosyodemografik ve klinik özelliklerin ilişkisine dair bulgular çelişkilidir. Bizim çalışmamızda ilişki saptanmamıştır. Bu konuyu aydınlatmak için daha fazla sayıda çalışmaya ihtiyaç vardır. MetS ile şizofreni alt tipleri ve şizofreni semptomları ilişkisiz gibi görünmektedir.

🔖

Cite This Article

SARISOY, G., BÖKE, Ö., ÖZTÜRK, A., AKKAYA, D., PAZVANTOĞLU, O., ŞAHİN, A. R. (2013). Şizofreni hastalarında metabolik sendrom sıklığının sosyodemografik ve klinik özelliklerle ilişkisi. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 26 - Sayı: 3, 267–275. https://ajindex.com/articles/222528

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull 2013; 39:306-318
  2. Riordan HJ, Antonini P, Murphy MF. Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. American Health & Drug Benefits 2011; 4:292-302
  3. Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, Bergman RN. Insulin sensitivity, insulin secretion, and abdominal fat: the insulin resistance atherosclerosis study (IRAS) Family study. Diabetes 2003; 52:2490-2496
  4. Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21:515-523
  5. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montoni VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and metaanalysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403-414
  6. Kozumplik O, Uzun S, Jakovljević M. Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics. Psychiatr Danub 2010; 22:69- 74
  7. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119:4-14
  8. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607
  9. Meyer J, Koro CE, L’Italien GJ. The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry 2005; 17:173-180
  10. Keltner NL. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics. Perspect Psychiatr Care 2006;42:204-207
  11. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA; CAFE Investigators. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111:9-16
  12. Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 2011; 26:291-302
  13. Subashini R, Deepa M, Padmavati R, Thara R, Mohan V. Prevalence of diabetes, obesity and metabolic syndrome in subjects with and without schizophrenia (CURES-104). J Postgrad Med 2011; 57:272-277
  14. Sugawara N, Yasui-Fu